Market Summary
Capital markets remain hesitant through H1 2023 as overall US life sciences venture capital and IPO activity has decreased substantially since the 2021 peak. Biotech enterprises should carefully time and execute financing transactions around accretive lifecycle events which maximize valuations and minimize dilution. The ability to successfully complete fundraising is key to long-term success.

Which Lifecycle Events are Most Accretive to Value Creation?

**Accretive**
Events which result in sustained value creation
- Partnerships
- Late-stage data readouts
- BLA approvals

**Already priced in**
Events considered table stakes
- BLA filings
- IND filings
- Orphan drug status designation
- Fast Track status designation

© Copyright 2023. Deloitte Development LLC. All Rights Reserved.
Maximizing Value Creation Through Capital Deployment

Key business decisions can be accretive or destructive to overall value creation. The deliberate deployment of capital to the right triggers aids in maximizing value creation and fundraising.

- Build vs. buy
- Multiple INDs or one leading asset
- CDMO strategy
- Clinical trial planning
- Manufacturing and supply chain
- Partnerships and collaborations
- Financing strategy
- Cost optimization

Aligning Operations with Lifecycle Events

Understanding the expected direction and magnitude of key lifecycle events unlocks value by:

- Aligning strategic planning and investment decisions with accretive lifecycle events
- Prioritizing capital budgeting and investment decisions with accretive lifecycle events
  - Actively managing costs with lower value creation
- Shaping investor sentiment and managing investor expectations around lifecycle events
- Mitigating financial risks by better understanding which key lifecycle events are most influential to value creation

You Might Be Asking... and We Can Help

- We have an upcoming lifecycle event, what do we need to do now to capitalize on it?
- How do we time financing and M&A activities with key life events?
- What does our commercial operating model look like?
- What is the framework for a successful partnership and collaboration agreement?
- What operational and scientific activities do we need to execute right the first time?
- What commercial, regulatory, quality, and finance capabilities do we need?

Start the conversation

Tailor the CGT Market Index to your company’s specific operating model—for example, insights specific to autologous, allogeneic, CDMOs, IPSC, gene editing, etc.

What is the CGT Market Index

The Cell and Gene Therapy (“CGT”) Market Index, a first of its kind, insight driven tool assists senior executives make strategic decisions by exploring value maximization opportunities during key life events for CGT companies.

Aligning strategic planning and investment decisions with accretive lifecycle events

Siddharth Aggarwal
Senior Manager Modeling and Valuation
Deloitte Risk & Financial Advisory LLP

Jennifer Laing
Managing Director & NextGen Therapies Practice Leader
Deloitte Consulting LLP

Amit Agarwal
Managing Director & NextGen Therapies Practice Leader
Deloitte Consulting LLP

Hussain Mooraj
Principal & NextGen Therapies Practice Leader
Deloitte Consulting LLP

You Might Be Asking... and We Can Help

- We have an upcoming lifecycle event, what do we need to do now to capitalize on it?
- How do we time financing and M&A activities with key life events?
- What does our commercial operating model look like?

What is the framework for a successful partnership and collaboration agreement?

- What operational and scientific activities do we need to execute right the first time?
- What commercial, regulatory, quality, and finance capabilities do we need?

Start the conversation

Tailor the CGT Market Index to your company’s specific operating model—for example, insights specific to autologous, allogeneic, CDMOs, IPSC, gene editing, etc.